Myasthenia Gravis Inebilizumab Trial (NCT04524273)

🧪 Interventions in This Study

• inebilizumab (DRUG)
• IV Placebo (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Diagnosis of MG with anti-AChR or anti-MuSK antibody.
2. MGFA Clinical Classification Class II, III, or IV.
3. MG-ADL score of 6 or greater at screening and at randomization with \> 50% of this score attributed to non-ocular items.
4. QMG score of 11 or greater.
5. Participants must be on:
6. Corticosteroids only, with no dose increase within 4 weeks prior to randomization, or
7. One allowed non-steroidal immunosuppressive therapy (IST), with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization, or
8. Combination of (1) corticosteroids with no dose increase within 4 weeks prior to randomization and (2) one allowed non-steroidal IST with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization. Allowed ISTs, alone or in combination with corticosteroids, are azathioprine, mycophenolate mofetil, and mycophenolic acid.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (104 Sites)

Showing the first 25 of 104 sites.

• Viela Bio Investigative Site - 1015 — Orange, California
• Viela Bio Investigative Site - 1002 — New Haven, Connecticut
• Viela Bio Investigative Center - 1024 — Washington D.C., District of Columbia
• Viela Bio Investigative Site - 1005 — Tampa, Florida
• Viela Bio Investigative Site - 1012 — Kansas City, Kansas
• Viela Bio Investigative Site - 1018 — Charlotte, North Carolina
• Viela Bio Investigative Site - 1025 — Canton, Ohio
• Viela Bio Investigative Site - 1001 — Cincinnati, Ohio
• Viela Bio Investigative Site - 1009 — Columbus, Ohio
• Viela Bio Investigative Site - 1008 — Pittsburgh, Pennsylvania
• Viela Bio Investigative Site - 1019 — Austin, Texas
• Viela Bio Investigative Site - 1003 — Houston, Texas
• Viela Bio Investigative Site - 1014 — San Antonio, Texas
• Viela Bio Investigative Site - 1017 — Salt Lake City, Utah
• Viela Bio Investigative Site - 1004 — Burlington, Vermont
• Viela Bio Investigative Site - 1006 — Richmond, Virginia
• Viela Bio Investigative Site - 2001 — Buenos Aires,
• VielaBio Investigative Site - 2002 — Buenos Aires,
• Viela Bio Investigative Site - 2003 — Buenos Aires,
• Viela Bio Investigative Site - 5203 — Grodno,
• Viela Bio Investigative Site - 5204 — Minsk,
• Viela Bio Investigative Site - 5201 — Vitebsk,
• VielaBio Investigative Site - 2201 — Porto Alegre,
• VielaBio Investigative Site - 2203 — Porto Alegre,
• VielaBio Investigative Site - 2207 — Ribeirão Preto,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myasthenia Gravis

• Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis — Saint Paul, Minnesota
• A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis — Phoenix, Arizona
• A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) — Colorado Springs, Colorado
• KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis — Los Angeles, California
• MuSK Myasthenia 1000 Study — Washington D.C., District of Columbia
• A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa — San Francisco, California

Explore by condition: All Myasthenia Gravis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.